We asked the @a16zbiohealth team about the big ideas they think startups in their field will tackle in 2023.
Here are 5 builder-worthy pursuits for the new year in bio and health tech 🧵👇
The biggest company in the world will be a consumer health tech company, wrote @vijaypande & @daisydwolf recently: a16z.com/2022/11/11/the-biggest-company-in-the-world/
Could 2023 be the year that company is founded?
Precision delivery of medicines has become an industry-stalling bottleneck, but @vintweeta & @beckypferdehirt hope to finally see a breakthrough that will unleash a landslide of queued-up therapeutic approaches to progress into the clinic.
.@vintweeta and Ben Portney expect to see advancements in chemical-induced proximity. They're especially on the lookout for molecules that can introduce or remove novel modifications to proteins, regulate gene activity, and target RNA directly.
The industry's appetite for science-native SaaS tools is accelerating, according to @jorgecondebio & @jayrughani, and they think it’s time for a modern bio software stack.
.@julesyoo & @justin_larkinMD are unabashedly value-based care optimists, but VBC done right is going to require purpose-built approaches built on a fundamentally different stack than what’s currently available.
Interested in more big ideas to come in tech and startups in the new year? Check out all the answers from a16z partners across our Consumer, Crypto, Fintech, Games, American Dynamism and Enterprise teams. a16z.com/2022/12/15/big-ideas-in-tech-2023/
None of the above should be taken as investment advice; please see a16z.com/disclosures for more information.
a16z
@a16z
we invest in software eating the world a16z.com/portfolio a16z.com/podcasts "The Ben & Marc Show": youtube.com/playlist?list=…